DE68928897D1 - Verfahren und system zur empfängnisverhütung - Google Patents

Verfahren und system zur empfängnisverhütung

Info

Publication number
DE68928897D1
DE68928897D1 DE68928897T DE68928897T DE68928897D1 DE 68928897 D1 DE68928897 D1 DE 68928897D1 DE 68928897 T DE68928897 T DE 68928897T DE 68928897 T DE68928897 T DE 68928897T DE 68928897 D1 DE68928897 D1 DE 68928897D1
Authority
DE
Germany
Prior art keywords
day
progestin
stage
composition
follow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68928897T
Other languages
English (en)
Other versions
DE68928897T2 (de
Inventor
Samuel A Pasquale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SAVIENT PHARMACEUTICALS, INC., EAST BRUNSWICK, US
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68928897(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of DE68928897D1 publication Critical patent/DE68928897D1/de
Application granted granted Critical
Publication of DE68928897T2 publication Critical patent/DE68928897T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
DE68928897T 1988-10-20 1989-10-19 Verfahren und system zur empfängnisverhütung Expired - Lifetime DE68928897T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/260,447 US4921843A (en) 1988-10-20 1988-10-20 Contraception system and method
PCT/US1989/004697 WO1990004330A1 (en) 1988-10-20 1989-10-19 Contraception system and method

Publications (2)

Publication Number Publication Date
DE68928897D1 true DE68928897D1 (de) 1999-02-18
DE68928897T2 DE68928897T2 (de) 1999-07-29

Family

ID=22989203

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68928897T Expired - Lifetime DE68928897T2 (de) 1988-10-20 1989-10-19 Verfahren und system zur empfängnisverhütung

Country Status (15)

Country Link
US (1) US4921843A (de)
EP (1) EP0397823B1 (de)
JP (1) JP3001216B2 (de)
KR (1) KR0182283B1 (de)
AT (1) ATE175353T1 (de)
AU (1) AU620940B2 (de)
CA (1) CA2001144C (de)
DE (1) DE68928897T2 (de)
FI (1) FI103951B (de)
HU (2) HUT51899A (de)
IL (1) IL92069A0 (de)
NZ (1) NZ231091A (de)
PT (1) PT92069B (de)
WO (1) WO1990004330A1 (de)
ZA (1) ZA897977B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
DE4104385C1 (de) * 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
DE4344405C2 (de) * 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
DE4411585A1 (de) * 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
US20050032756A1 (en) * 1995-10-28 2005-02-10 Michael Dittgen Multistage preparation for contraception based on natural estrogens
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
US6451778B1 (en) 1996-07-26 2002-09-17 Wyeth Oral contraceptive
US6479475B1 (en) 1996-07-26 2002-11-12 Wyeth Oral contraceptive
WO1998004267A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Progestin/estrogen oral contraceptive
US5888543A (en) * 1996-07-26 1999-03-30 American Home Products Corporation Oral contraceptives
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
WO2001030355A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
ATE279198T1 (de) * 1997-08-27 2004-10-15 Ortho Mcneil Pharm Inc Kombinationen von endometrium schonenden gestagenen und endometrium atrophisierenden gestagenen mit estrogenen, bei der oralen empfängnisverhütung
US6251956B1 (en) 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
WO2000028995A1 (en) * 1998-11-12 2000-05-25 Warner Chilcott Laboratories Ireland Limited Graduated progestin contraceptive
US6214815B1 (en) 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
KR100533346B1 (ko) * 1999-02-26 2005-12-05 시오노기 앤드 컴파니, 리미티드 복용성을 개량한 츄잉형 소프트 캡슐제 및 그 제조방법
US6660726B2 (en) * 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US7459445B2 (en) * 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US7989436B2 (en) * 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
ES2208518T3 (es) * 2001-05-23 2004-06-16 Pantarhei Bioscience B.V. Medio y metodo anticonceptivo hormonal.
CA2468748C (en) * 2001-12-05 2010-01-26 Barr Laboratories, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
JP2004140323A (ja) * 2002-08-20 2004-05-13 Sharp Corp 半導体レーザ装置およびその製造方法
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
WO2004091535A2 (en) * 2003-04-11 2004-10-28 Barr Laboratories, Inc. Methods of administering estrogens and progestins
CA2542854C (en) * 2003-11-14 2012-04-17 Warner Chilcott Company, Inc. Graduated estrogen contraceptive
EP1550447A1 (de) * 2004-01-02 2005-07-06 Schering Aktiengesellschaft Menstruationszykluskontrolle und Verbesserung der weiblichen Empfängnisrate
EP1735056B1 (de) * 2004-03-19 2012-10-24 Warner Chilcott Company, LLC Mehrphasige orale kontrazeptionsmethode mit verlängertem zyklus
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
EP1853272A1 (de) * 2005-02-03 2007-11-14 Duramed Pharmaceuticals, Inc. Zusammensetzungen aus unkonjugierten östrogenen und anwendungsverfahren dafür
US7704984B2 (en) * 2005-04-22 2010-04-27 Warner Chilcott Company, Llc Extended estrogen dosing contraceptive regimen
US8153616B2 (en) * 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) * 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6615481A (de) * 1966-11-02 1968-05-03
US3409721A (en) * 1967-09-15 1968-11-05 Neomed Lab Inc Oral dosage system effective to control the reproduction cycle
US4372951A (en) * 1979-10-11 1983-02-08 Nichols Vorys Vaginal delivery for physiologic follicular-luteal steroid treatment
US4628051A (en) * 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) * 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3347125A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption

Also Published As

Publication number Publication date
WO1990004330A1 (en) 1990-05-03
KR900701277A (ko) 1990-12-01
IL92069A0 (en) 1990-07-12
EP0397823B1 (de) 1999-01-07
HU211931A9 (en) 1996-01-29
ATE175353T1 (de) 1999-01-15
AU620940B2 (en) 1992-02-27
PT92069B (pt) 1995-06-30
FI103951B1 (fi) 1999-10-29
NZ231091A (en) 1995-12-21
CA2001144C (en) 1999-07-20
HUT51899A (en) 1990-06-28
AU4497089A (en) 1990-05-14
KR0182283B1 (ko) 1999-05-01
JP3001216B2 (ja) 2000-01-24
US4921843A (en) 1990-05-01
JPH03502932A (ja) 1991-07-04
FI103951B (fi) 1999-10-29
EP0397823A1 (de) 1990-11-22
FI903106A0 (fi) 1990-06-20
ZA897977B (en) 1990-07-25
DE68928897T2 (de) 1999-07-29
PT92069A (pt) 1990-04-30
EP0397823A4 (en) 1991-04-03
CA2001144A1 (en) 1990-04-20

Similar Documents

Publication Publication Date Title
DE68928897T2 (de) Verfahren und system zur empfängnisverhütung
DK365887D0 (da) Kombinationsdoseringsform til hormonbehandling af kvinder i prae-menopausen
ATE216241T1 (de) Sehr niedrigdosiertes orales kontrazeptiv mit weniger menstruationsblutungen und verzögerter wirkung
KR960706344A (ko) 호르몬 피임 및/또는 여드름 치료 수단 및 방법(means and method for hormonal contraception and/or the treatment of acne)
ATE239483T1 (de) Pharmazeutisches kombinationspräparat, kit und methode zur hormonalen kontrazeption
CA2188907A1 (en) Combination compound for contraception based on natural estrogen
TR199802705T2 (xx) Progestojen-anti-progestojen k�r�
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
MD1504F2 (ro) Aplicare a dimeticonei în calitate de ingredient activ în compoziţie farmaceutică pentru tratamentul aftelor şi stomatitelor şi compoziţie farmaceutică conţinând dimeticonă
PT94787A (pt) Processo de preparacao de composicoes farmaceuticas para administracao transdermica de corticosteroides e de compostos com actividade fisiologica semelhante
ATE73664T1 (de) Arzneimittel zur regulierung der hormonellen sekretionen und zur behandlung der weiblichen sterilitaet.
TW324663B (en) Interferon-ω(IFN-ω) as anti-HIV (human immune deficiency virus) agent
TH14144EX (th) การลดการสูญเสียโลหิตแบบไหลออกที่เกิดจากการใช้โปรเกสทิน
RU94040720A (ru) Экстроген (прогестин) антипрогестиновый, способ пероральной контрацепции и регулирования менструаций, фармацевтическая композиция и набор лекарственных средств

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SAVIENT PHARMACEUTICALS, INC., EAST BRUNSWICK, US

8328 Change in the person/name/address of the agent

Representative=s name: MEISSNER, BOLTE & PARTNER GBR, 80538 MUENCHEN